CN114437967A - 乳酸片球菌AUd2101及在制备治疗犬腹泻制剂中的应用 - Google Patents
乳酸片球菌AUd2101及在制备治疗犬腹泻制剂中的应用 Download PDFInfo
- Publication number
- CN114437967A CN114437967A CN202210013388.3A CN202210013388A CN114437967A CN 114437967 A CN114437967 A CN 114437967A CN 202210013388 A CN202210013388 A CN 202210013388A CN 114437967 A CN114437967 A CN 114437967A
- Authority
- CN
- China
- Prior art keywords
- aud2101
- pediococcus acidilactici
- preparation
- diarrhea
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000191998 Pediococcus acidilactici Species 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 27
- 241000589875 Campylobacter jejuni Species 0.000 claims abstract description 12
- 241000607142 Salmonella Species 0.000 claims abstract description 12
- 241000607768 Shigella Species 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims description 16
- 241000282465 Canis Species 0.000 claims description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 241000588724 Escherichia coli Species 0.000 abstract description 10
- 244000052616 bacterial pathogen Species 0.000 abstract description 4
- 238000004321 preservation Methods 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 16
- 239000006041 probiotic Substances 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- 238000012258 culturing Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000000529 probiotic effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 239000003833 bile salt Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000003794 Gram staining Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000009631 Broth culture Methods 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960000740 enrofloxacin Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229960000603 cefalotin Drugs 0.000 description 2
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
分离株 | 菌株 | 相似度 | 登录号 |
乳酸片球菌AUd2101 | 乳酸片球菌 | 99% | NR_042057.1 |
菌株 | 青霉素 | 氨苄西林 | 头孢噻吩 | 恩诺沙星 | 万古霉素 | 庆大霉素 | 环丙沙星 |
AUd2101 | S | S | S | I | R | R | R |
分组 | 1d | 2d | 3d | 4d | 5d | 6d | 7d | 8d | 9d |
对照组 | 100% | 100% | 100% | 90% | 80% | 50% | 30% | 10% | 0 |
Aud2101 | 100% | 100% | 100% | 80% | 50% | 20% | 0 | 0 | 0 |
免疫因子(g/L) | 治疗前 | 治疗后 |
IgA | 1.57±0.07<sup>A</sup> | 1.27±0.08<sup>B</sup> |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210013388.3A CN114437967B (zh) | 2022-01-06 | 2022-01-06 | 乳酸片球菌AUd2101及在制备治疗犬腹泻制剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210013388.3A CN114437967B (zh) | 2022-01-06 | 2022-01-06 | 乳酸片球菌AUd2101及在制备治疗犬腹泻制剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114437967A true CN114437967A (zh) | 2022-05-06 |
CN114437967B CN114437967B (zh) | 2023-07-18 |
Family
ID=81367588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210013388.3A Active CN114437967B (zh) | 2022-01-06 | 2022-01-06 | 乳酸片球菌AUd2101及在制备治疗犬腹泻制剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114437967B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117467581A (zh) * | 2023-12-22 | 2024-01-30 | 山东威曼宠物食品有限公司 | 一种提高犬免疫力的乳酸片球菌King73及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107404913A (zh) * | 2015-02-11 | 2017-11-28 | 科.汉森有限公司 | 通过红葡萄酒提取物和包含至少一种产生细菌素的乳酸细菌菌株的培养物的组合降低发酵食品中革兰氏阴性细菌的浓度 |
CN108271984A (zh) * | 2018-01-02 | 2018-07-13 | 中国农业科学院农产品加工研究所 | 红景天固体饮料及其制备方法 |
CN112956622A (zh) * | 2021-02-25 | 2021-06-15 | 中国农业科学院农产品加工研究所 | 一种薯类发酵饮料和薯渣粉连续生产的方法及其制备的产品 |
WO2021250284A1 (en) * | 2020-06-12 | 2021-12-16 | Eligo Bioscience | Specific decolonization of antibiotic resistant bacteria for prophylactic purposes |
WO2022058798A2 (en) * | 2020-09-18 | 2022-03-24 | Biocc Oü | Microorganism strain pediococcus acidilactici tak 589 coccobest as an antimicrobial and antioxidant probiotic |
-
2022
- 2022-01-06 CN CN202210013388.3A patent/CN114437967B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107404913A (zh) * | 2015-02-11 | 2017-11-28 | 科.汉森有限公司 | 通过红葡萄酒提取物和包含至少一种产生细菌素的乳酸细菌菌株的培养物的组合降低发酵食品中革兰氏阴性细菌的浓度 |
US20190029279A1 (en) * | 2015-02-11 | 2019-01-31 | Chr. Hansen A/S | Reduction of the concentration of gram-negative bacteria in a fermented food product by the combination of red wine extract and a culture comprising at least one bacteriocin-producing lactic acid bacterial strain |
CN108271984A (zh) * | 2018-01-02 | 2018-07-13 | 中国农业科学院农产品加工研究所 | 红景天固体饮料及其制备方法 |
WO2021250284A1 (en) * | 2020-06-12 | 2021-12-16 | Eligo Bioscience | Specific decolonization of antibiotic resistant bacteria for prophylactic purposes |
WO2022058798A2 (en) * | 2020-09-18 | 2022-03-24 | Biocc Oü | Microorganism strain pediococcus acidilactici tak 589 coccobest as an antimicrobial and antioxidant probiotic |
CN112956622A (zh) * | 2021-02-25 | 2021-06-15 | 中国农业科学院农产品加工研究所 | 一种薯类发酵饮料和薯渣粉连续生产的方法及其制备的产品 |
Non-Patent Citations (4)
Title |
---|
RINE CHRISTOPHER REUBEN等: "Isolation, characterization, and assessment of lactic acid bacteria toward their selection as poultry probiotics", BMC MICROBIOLOGY, vol. 9, no. 1, pages 1 - 20 * |
周倩;朱琦琦;何维;余冬梅;赵俊梅;胡欣洁;: "一株产纤溶酶凝结芽孢杆菌的筛选及其生物学特性", 基因组学与应用生物学, no. 04, pages 182 - 189 * |
陈卫;翟齐啸;: "益生菌对食品安全危害因子的拮抗与减除", 中国食品学报, no. 11, pages 1 - 10 * |
魏雪等: "犬源乳酸菌的分离鉴定及益生功能评价", 中国优秀硕士学位论文全文数据库基础科学辑(电子期刊), pages 006 - 2297 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117467581A (zh) * | 2023-12-22 | 2024-01-30 | 山东威曼宠物食品有限公司 | 一种提高犬免疫力的乳酸片球菌King73及其应用 |
CN117467581B (zh) * | 2023-12-22 | 2024-03-08 | 山东威曼宠物食品有限公司 | 一种提高犬免疫力的乳酸片球菌King73及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114437967B (zh) | 2023-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112011481B (zh) | 一株防治畜禽细菌性腹泻的罗伊氏乳杆菌及其应用 | |
CN114437993B (zh) | 罗伊氏乳杆菌及其在制备预防猫腹泻制剂中的应用 | |
CN116083300B (zh) | 一种防治犬腹泻的益生菌复合制剂及其应用 | |
CN111778180B (zh) | 一种母乳源植物乳杆菌及其应用 | |
CN112574929B (zh) | 一株吉林类芽孢杆菌ypg26及其医用用途 | |
CN110004072B (zh) | 一株益生性粪肠球菌分离株a3-1及其应用 | |
CN111100821A (zh) | 一种链球菌及其应用 | |
CN114437967B (zh) | 乳酸片球菌AUd2101及在制备治疗犬腹泻制剂中的应用 | |
CN110028560B (zh) | 一种凝结芽孢杆菌产的细菌素及其应用 | |
CN114437964A (zh) | 一株贝莱斯株芽孢杆菌及其应用 | |
KR101098946B1 (ko) | 신규한 락토바실러스 살리바리우스 균주 및 이를 함유하는 사료첨가제 조성물 | |
CN113151035B (zh) | 一种解淀粉芽孢杆菌、筛选方法、鉴定方法及应用 | |
CN111778178B (zh) | 海洋灰平链霉菌hn60在抗细菌方面的应用 | |
CN109897800B (zh) | 一株富硒坚强肠球菌a8-1及其应用 | |
CN116478873B (zh) | 一种民猪肠道中可抑制多种有害菌生长的贝莱斯芽孢杆菌 | |
CN114908009B (zh) | 一株口粘液乳杆菌pr63及其应用 | |
CN113151113B (zh) | 一株抑菌能力强的丁酸梭菌及其应用 | |
CN114717150B (zh) | 一种植物乳杆菌crs33及其应用 | |
CN113061550B (zh) | 一株乳杆菌新菌株z6及其在食品中的应用 | |
CN116496929B (zh) | 一种猪源芽孢杆菌及其应用 | |
CN117070423B (zh) | 一株植物乳植杆菌LPPerfectus001及其应用 | |
CN114874952B (zh) | 干酪乳杆菌hjd及其应用 | |
CN116970513B (zh) | 一株植物乳植杆菌sq6及其应用 | |
CN110438043B (zh) | 一种甲基营养型芽孢杆菌yfi-1及在制备水产细菌抑菌剂中的应用 | |
Abimbola et al. | Antibiotics resistance and phenotypic virulence factors of Vibrio species isolated from poultry litters at Obafemi Awolowo University, research farm. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20220506 Assignee: ANHUI JINLAC BIOTECH LTD. Assignor: AUSNUTRIA DAIRY (CHINA) Co.,Ltd.|INSTITUTE OF FOOD SCIENCE AND TECHNOLOGY, CHINESE ACADEMY OF AGRICULTURAL SCIENCES Contract record no.: X2023980043948 Denomination of invention: Lactobacillus AUd2101 and its application in the preparation of preparations for treating canine diarrhea Granted publication date: 20230718 License type: Common License Record date: 20231019 |